Dr. Vimal Mehta | CEO |
Richard Steinhart | CFO |
Will Kane | Chief Commercial Officer |
Dr. Vince O’Neill | Chief Medical Officer |
Dr. Frank Yocca | Chief Scientific Officer |
Dr. Rob Risinger | SVP, Clinical Development |
Greg Harrison | Bank of America |
Ram Selvaraju | H.C. Wainwright |
Eddie Hickman | Guggenheim |
Sumant Kulkarni | Canaccord |
Anita Dushyanth | Berenberg Capital Markets |
Samir Devani | Rx Securities |
Good morning, and welcome to the BioXcel Therapeutics Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Just to remind everyone, certain matters discussed in today’s conference call and/or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial performance of the Company. Actual results could differ materially from those anticipated in these forward-looking statements. The risk factors that may affect results are detailed in the Company’s most recent public filings with the U.S.